Holen Sie sich die Stockscreener-App
3.35
10.93%
0.33
Handel nachbörslich:
3.40
0.05
+1.49%
Schlusskurs vom Vortag:
$3.02
Offen:
$3.2801
24-Stunden-Volumen:
175.71K
Relative Volume:
0.07
Marktkapitalisierung:
$4.46M
Einnahmen:
$9.81M
Nettoeinkommen (Verlust:
$-26.16M
KGV:
-0.0864
EPS:
-38.77
Netto-Cashflow:
$-17.45M
1W Leistung:
+18.37%
1M Leistung:
+30.86%
6M Leistung:
-97.00%
1J Leistung:
-98.91%
1-Tages-Spanne:
$3.28
$3.3518
1-Wochen-Bereich:
$2.78
$3.3518
52-Wochen-Spanne:
$2.23
$323.35
Reshape Lifesciences Inc Stock (RSLS) Company Profile
Firmenname
Reshape Lifesciences Inc
Sektor
Branche
Telefon
949-429-6680
Adresse
1001 CALLE AMANECER, SAN CLEMENTE
Vergleichen Sie RSLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
3.35 | 7.21M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
125.83 | 218.75B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
107.76 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
400.93 | 151.01B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.01 | 117.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.91 | 44.76B | 5.54B | 4.18B | 623.10M | 7.00 |
Reshape Lifesciences Inc Aktie (RSLS) Neueste Nachrichten
Is ReShape Lifesciences Inc. a good long term investmentHigh-margin investment plays - Autocar Professional
ReShape Lifesciences Inc. Stock Analysis and ForecastExplosive trading opportunities - jammulinksnews.com
What analysts say about ReShape Lifesciences Inc. stockExceptional risk-adjusted gains - printweek.in
ReShape's New Lap-Band 2.0 FLEX Targets GLP-1 Era: Top Surgeons Gather for Groundbreaking Summit - Stock Titan
ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit - GlobeNewswire
ReShape Lifesciences Hosts Special Meeting of Stockholders on July 24, 2025 - AInvest
ReShape Lifesciences Board Unanimously Recommends Merger with Vyome Therapeutics and Sale of Assets to Biorad Medisys - Nasdaq
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System - Yahoo.co
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025 - GlobeNewswire
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025 - Benzinga
ReShape Lifesciences Strategic Transformation: Board and Proxy Advisors Unite Behind Vyome Merger - Stock Titan
What drives ReShape Lifesciences Inc. stock priceUnmatched profit growth - jammulinksnews.com
How high can ReShape Lifesciences Inc. stock price go in 2025Free Access to Community - Newser
ReShape Lifesciences Announces Merger with Vyome Therapeutics - The Globe and Mail
Why ReShape Lifesciences Inc. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser
What makes ReShape Lifesciences Inc. stock price move sharplyFree Join Group - Newser
How ReShape Lifesciences Inc. stock performs during market volatilityFree Capital Growth Strategies - Newser
ReShape Lifesciences announces 1-for-25 reverse stock split By Investing.com - Investing.com Nigeria
ReShape Lifesciences Loans $200K to Vyome Therapeutics - TipRanks
ReShape Lifesciences to receive patent for swallowable balloon device - Investing.com
ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System - The Manila Times
Game-Changing Patent: ReShape's New Self-Degrading Weight Loss Balloon Could Transform Obesity Treatment - Stock Titan
RSLS 425及美國證券交易委員會申報文件 - Yahoo 財經
ReShape Lifesciences: Navigating Regulatory Recovery – Is This Turnaround Sustainable? - AInvest
ReShape Lifesciences regains Nasdaq compliance after equity raises By Investing.com - Investing.com South Africa
ReShape Lifesciences regains Nasdaq compliance after equity raises - Investing.com
ReShape Lifesciences cuts workforce to save $750k annually - Investing.com
About Us - FinancialContent
Revolutionary Diabetes Treatment: ReShape's New Neuromodulation Tech Targets Blood Sugar Without Drugs - Stock Titan
ReShape Lifesciences boosts stockholders’ equity above Nasdaq minimum By Investing.com - Investing.com India
ReShape Lifesciences boosts stockholders’ equity above Nasdaq minimum - Investing.com
ReShape Lifesciences Raises Equity to Avoid Delisting - TipRanks
ReShape Lifesciences Stock Soars On Distribution Agreement With Recon Supply, Draws Retail Applause - MSN
Reshape Lifesciences Stock Price, Quotes and Forecasts | NASDAQ:RSLS - Benzinga
Why Did ReShape Lifesciences Plunge 12.54%? Public Offering Concerns - AInvest
ReShape Lifesciences Closes $2.6M Stock Offering - TipRanks
Finanzdaten der Reshape Lifesciences Inc-Aktie (RSLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):